NCT01472783View on ClinicalTrials.gov

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

August 31, 2016

Conditions
Recurrent, Epithelial Ovarian Cancer
Interventions
DRUG

Veliparib

Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.

Trial Locations (1)

7100

Department of Oncology, Vejle Hospital, Vejle

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Vejle Hospital

OTHER